News and Press Releases
Greenphire Announces Acquisition of Clincierge to Enhance Clinical Trial Support Services
Addition enables sponsors to solve the number one clinical trial participant obstacle – transportation, with a single industry-leading solution 1 February 2024 -- Pennsylvania, US -- Greenphire, a leading innovator in...
Category: Clinical Trials
Posted: February 1, 2024
Almost half of Brits think the Government is doing too little to encourage development of new medicines in the UK
25 January -- London, UK -- Recent YouGov polling commissioned by clinical trials start-up Lindus Health has found that 47% of Brits want the Government to be doing more to...
Category: Pharmaceutical
Posted: January 25, 2024
Phesi releases 2023 analysis of clinical development; breast cancer remains most studied disease area for third year
Annual analysis of data from 95 million patients shows signs of post-pandemic recovery for clinical development industry, but trial cancellation rates at phase 2 remain high 16 January 2024 --...
Category: Clinical Trials
Posted: January 16, 2024
AiCuris Received €15m Milestone Payment from Licensing Partner MSD Following EMA Approval of PREVYMIS for Prevention of CMV Infection in High-Risk Adult Kidney Transplant Recipients
PREVYMIS now approved in the US and Europe for prophylaxis of Cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]) EMA approval...
Category: Pharmaceutical
Posted: January 9, 2024
Friedrich-Ebert-Str. 475 / Building 302 42117 Wuppertal Germany
Headlands Research Announces Partnership with Sahara Behavioral Health
The collaboration improves access to clinical research and investigational treatments while supporting participant recruitment efforts in Arizona 4 January 2024 -- California, US -- Headlands Research, a leading multinational network...
Category: Clinical Trials
Posted: January 5, 2024
Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide
5 January 2024 -- Helsinki, Finland -- Nanoform Finland, the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate...
Category: Clinical Trials
Posted: January 5, 2024
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Lazertinib, in combination with RYBREVANT (amivantamab), for the First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer
The submission is supported by data from the Phase 3 MARIPOSA study, which featured in a Late-Breaking Presidential Symposium session at the 2023 ESMO CongressLazertinib is a highly selective, central...
Category: Clinical Trials
Posted: December 21, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Lindus Health and Thirty Madison complete enrolment of personalised dermatology care pilot study
14 December 2023 -- London, UK -- Clinical trial company Lindus Health and Thirty Madison, a US-based family of specialised healthcare brands, have today announced the completion of enrolment of...
Category: Clinical Trials
Posted: December 14, 2023
PlaqueTec recruits first ten patients in BIOPATTERN trial
Trial to investigate atherosclerotic cardiovascular diseases receives MHRA approval to continue recruitment towards 300-patient target Unique PlaqueTec Liquid Biopsy System will be used to collect blood samples containing biomolecules localising...
Category: Clinical Trials
Posted: November 29, 2023
Exonate announces successful completion of phase 1b/2a trial in diabetic macular oedema
Lead ophthalmology candidate EXN407 has potential to be the first topical treatment for diabetic retinopathy/diabetic macular oedema EXN407 met all endpoints and displayed encouraging biological activity in diabetic patients with...
Category: Clinical Trials
Posted: November 28, 2023
Commercial study set up times reduced by a third, according to new data
26 October 2023 -- London, England -- New data from the National Institute for Health and Care Research (NIHR) shows that the National Contract Value Review has significantly reduced the...
Category: Clinical Trials
Posted: October 26, 2023
Results from Phase 2 THOR-2 Study Showed Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with Erdafitinib Versus Chemotherapy
Data from Cohort 1 of the phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical standard-of-care chemotherapy 21 October 2023 --...
Category: Clinical Trials
Posted: October 23, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Mundipharma and Cidara Therapeutics receive positive CHMP opinion forrezafungin for the treatment of Invasive Candidiasis in adults
The opinion was based on positive results from the pivotal ReSTORE phase 3 clinicaltrial and supported by the STRIVE phase 2 clinical trials and extensive nonclinicaldevelopment programme If approved by...
Category: Biotechnology
Posted: October 17, 2023
pharmaand GmbH Receives Positive CHMP Opinion for Rubraca (rucaparib) as a First-Line Maintenance Treatment in Advanced Ovarian Cancer
CHMP positive opinion based on the results from Phase 3 ATHENA-MONO trial European Commission (EC) approval decision expected in the coming months This is the first rucaparibregulatory milestone since being...
Category: Pharmaceutical
Posted: October 17, 2023
AstraZeneca reinforces commitment to protecting the most vulnerable from serious infectious diseases at IDWeek 2023
Real-world data from INFORM study demonstrate increased risk of severe COVID-19 outcomes among all individuals with immunocompromising conditions and highlight need for additional protection FluMist Quadrivalent data support the potential...
Category: Clinical Trials
Posted: October 12, 2023
PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA UK
